Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.

By Pei Chen, Juei-Jueng Lin, C. Lu, C. Ong, P. Hsieh, Chih-Chao Yang, C. Tai, Shey‐Lin Wu, Cheng-Hsien Lu, Y. Hsu and 23 more. New England Journal of Medicine, 2011

654 citations recorded by the source corpus.

Subfields: Dermatology, Pharmacology, Toxicology

View Paper: https://www.semanticscholar.org/paper/666513321157fb2bd08bff927d717ec4863806c5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Demoly
2. N. Adkinson
3. G. Malhi
4. K. Brockow
5. M. Castells
6. W. Pichler
7. A. Chiriac
8. P. Greenberger

Citations in the corpus

• Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “It is now recommended such testing be carried out prior to prescribing carbamazepine (Chen et al., 2011).”
• International Consensus on drug allergy (2014, background): “The same is now true for the drug carbamazepine in Han Chinese and the allele B*1502 (101).”
• HLA-A★3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans (2011, neutral): “In this issue of the Journal, a report describes how prospective HLA-B*1502 typing can prevent carbamazepine-induced SJS–TEN in Han Chinese populations.(5) We propose that HLA-A*3101 is clinically relevant as a marker to predict hypersensitivity reactions.”